search
Back to results

Light-emitting Diodes (LED) Phototherapy for Hyperbilirubinemia of Term Newborn (DELF)

Primary Purpose

Hyperbilirubinemia

Status
Terminated
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Phototherapy
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hyperbilirubinemia focused on measuring Jaundice, Hyperbilirubinemia, Phototherapy, term newborn, LED, Fluorescent lamps

Eligibility Criteria

35 Weeks - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Newborns in the hospital SAINT ANTOINE maternity wards
  • Gestational age of 35w or more
  • Healthy (no hypoxemia, no hypotonia, no abnormalities of thermic regulation, no infection or dehydration)
  • No foeto-maternal incompatibility in rhesus or kell group
  • With bilirubin level at 48h of 220µmoles/l or more if born at 38W or more or of 200µmoles/l or more if born between 35 and 38 W
  • Parental information done and signed consent obtained
  • Parents affiliated to social security

Exclusion Criteria:

  • Conjugated bilirubin level at 25µmol/l or more
  • Total bilirubin level over 300µmol/l indicating "intensive phototherapy"
  • Baby treated by phototherapy in the days before inclusion
  • Severe haemolytic disease with anemia below 14g/land or hyperbilirubinemia before 48h of life), rhesus or kell incompatibility
  • Parents who could not understand the information or sign the consent.

Sites / Locations

  • CNRHP, Saint Antoine Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

LEDDYBLOO®

Double BILITRON®

Futura®

Arm Description

LEDDYBLOO® phototherapy device equipped with 20 at 30 blue and white LEDs

Double BILITRON® phototherapy corresponding to two small ramps associated together each one equipped of 5 blue LEDS

Future phototherapy device equipped with 8 fluorescent tubes

Outcomes

Primary Outcome Measures

Bilirubinemia

Secondary Outcome Measures

Evolution of bilirubinemia according to the device used
Hyperbilirubinemia rebound according to the device used

Full Information

First Posted
June 2, 2010
Last Updated
December 10, 2012
Sponsor
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT01136577
Brief Title
Light-emitting Diodes (LED) Phototherapy for Hyperbilirubinemia of Term Newborn
Acronym
DELF
Official Title
Comparison of Light-emitting Diodes (LED) Phototherapy Versus Fluorescent Lamps Phototherapy for Treatment of Hyperbilirubinemia in Term Newborn
Study Type
Interventional

2. Study Status

Record Verification Date
December 2012
Overall Recruitment Status
Terminated
Study Start Date
January 2010 (undefined)
Primary Completion Date
October 2011 (Actual)
Study Completion Date
March 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Phototherapy is almost (beside exchange transfusion) the unique treatment for hyperbilirubinemia of the newborn. Its efficacy to decrease bilirubin level (because the light interacts with bilirubin at the skin level to transform it in water soluble products eliminated in urine and stools without liver metabolism) relies on the irradiance dispensed at the skin level by the device (in the 430-490nm range) and on the exposed surface of the baby. In the past years, technology of phototherapy devices moved from fluorescent lamps to LED, improving the amount of light energy emitted but on a smaller surface. The purpose of the study is to compare the efficacy of three ramps of phototherapy, one equipped with fluorescent tubes and two with LED (in a different technological settings) in the treatment of term (35 GW or more) healthy newborn suffering hyperbilirubinemia after 2days of life.
Detailed Description
Term and healthy newborns on maternity wards in SAINT-ANTOINE hospital are checked everyday for jaundice with bilirubinometer JM-103®. If indicated (nomogram included in patient charts), a plasmatic bilirubin level is performed. If the baby is two days old or more with a bilirubin level indicating standard phototherapy (by opposition to intensive phototherapy), the parents are informed of the research protocol and after obtention of parental consent, the baby is included. The newborn is admitted in the neonatology unit and randomised in one of the three phototherapy devices group. Plasmatic bilirubin levels are checked at 6,12 and 24 and 48 hours of phototherapy. At 12 hours of phototherapy, a biological checking is performed to address the etiology of the jaundice. The next plasmatic bilirubin level is performed at 72h after inclusion. During phototherapy treatment the baby is continuously monitored. Phototherapy is stopped when bilirubin level is below 200µmol/l. If the bilirubin level is increasing under one of this ramps or does not decrease at H24, the baby will be immediately move on intensive phototherapy and participation at the research protocol interrupted. Twenty four hours after the end of phototherapy treatment, plasmatic bilirubin level is checked to confirm the end of jaundice and statement is made for jaundice origin. The total duration of participation of a baby at this study is 72 hours.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hyperbilirubinemia
Keywords
Jaundice, Hyperbilirubinemia, Phototherapy, term newborn, LED, Fluorescent lamps

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
44 (Actual)

8. Arms, Groups, and Interventions

Arm Title
LEDDYBLOO®
Arm Type
Experimental
Arm Description
LEDDYBLOO® phototherapy device equipped with 20 at 30 blue and white LEDs
Arm Title
Double BILITRON®
Arm Type
Experimental
Arm Description
Double BILITRON® phototherapy corresponding to two small ramps associated together each one equipped of 5 blue LEDS
Arm Title
Futura®
Arm Type
Experimental
Arm Description
Future phototherapy device equipped with 8 fluorescent tubes
Intervention Type
Device
Intervention Name(s)
Phototherapy
Intervention Description
Phototherapy devices of ramp type placed over the incubator to treat with light in the 420-490nm range one face of the naked baby suffering jaundice.
Primary Outcome Measure Information:
Title
Bilirubinemia
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Evolution of bilirubinemia according to the device used
Time Frame
6, 12,24, 48, 72 hours
Title
Hyperbilirubinemia rebound according to the device used
Time Frame
24 and 48 hours after discontinuation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Weeks
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Newborns in the hospital SAINT ANTOINE maternity wards Gestational age of 35w or more Healthy (no hypoxemia, no hypotonia, no abnormalities of thermic regulation, no infection or dehydration) No foeto-maternal incompatibility in rhesus or kell group With bilirubin level at 48h of 220µmoles/l or more if born at 38W or more or of 200µmoles/l or more if born between 35 and 38 W Parental information done and signed consent obtained Parents affiliated to social security Exclusion Criteria: Conjugated bilirubin level at 25µmol/l or more Total bilirubin level over 300µmol/l indicating "intensive phototherapy" Baby treated by phototherapy in the days before inclusion Severe haemolytic disease with anemia below 14g/land or hyperbilirubinemia before 48h of life), rhesus or kell incompatibility Parents who could not understand the information or sign the consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anne Cortey, Doctor
Organizational Affiliation
APHP
Official's Role
Principal Investigator
Facility Information:
Facility Name
CNRHP, Saint Antoine Hospital
City
Paris
ZIP/Postal Code
75012
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
15231951
Citation
American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004 Jul;114(1):297-316. doi: 10.1542/peds.114.1.297. Erratum In: Pediatrics. 2004 Oct;114(4):1138.
Results Reference
background
PubMed Identifier
11275655
Citation
Bertini G, Dani C, Pezzati M, Rubaltelli FF. Prevention of bilirubin encephalopathy. Biol Neonate. 2001;79(3-4):219-23. doi: 10.1159/000047095.
Results Reference
background
PubMed Identifier
17297614
Citation
Bertini G, Perugi S, Elia S, Pratesi S, Dani C, Rubaltelli FF. Transepidermal water loss and cerebral hemodynamics in preterm infants: conventional versus LED phototherapy. Eur J Pediatr. 2008 Jan;167(1):37-42. doi: 10.1007/s00431-007-0421-3. Epub 2007 Feb 13.
Results Reference
background
PubMed Identifier
11230622
Citation
Bertini G, Dani C, Tronchin M, Rubaltelli FF. Is breastfeeding really favoring early neonatal jaundice? Pediatrics. 2001 Mar;107(3):E41. doi: 10.1542/peds.107.3.e41.
Results Reference
background
PubMed Identifier
9917432
Citation
Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics. 1999 Jan;103(1):6-14. doi: 10.1542/peds.103.1.6.
Results Reference
background
PubMed Identifier
17676232
Citation
Bhutani VK, Johnson L. Prevention of severe neonatal hyperbilirubinemia in healthy infants of 35 or more weeks of gestation: implementation of a systems-based approach. J Pediatr (Rio J). 2007 Jul-Aug;83(4):289-93. doi: 10.2223/JPED.1673. No abstract available.
Results Reference
background
PubMed Identifier
18204221
Citation
Bhutani VK, Maisels MJ, Stark AR, Buonocore G; Expert Committee for Severe Neonatal Hyperbilirubinemia; European Society for Pediatric Research; American Academy of Pediatrics. Management of jaundice and prevention of severe neonatal hyperbilirubinemia in infants >or=35 weeks gestation. Neonatology. 2008;94(1):63-7. doi: 10.1159/000113463. Epub 2008 Jan 17.
Results Reference
background
PubMed Identifier
15275978
Citation
Bhutani VK, Johnson LH, Keren R. Diagnosis and management of hyperbilirubinemia in the term neonate: for a safer first week. Pediatr Clin North Am. 2004 Aug;51(4):843-61, vii. doi: 10.1016/j.pcl.2004.03.011.
Results Reference
background
PubMed Identifier
15716604
Citation
Chang YS, Hwang JH, Kwon HN, Choi CW, Ko SY, Park WS, Shin SM, Lee M. In vitro and in vivo efficacy of new blue light emitting diode phototherapy compared to conventional halogen quartz phototherapy for neonatal jaundice. J Korean Med Sci. 2005 Feb;20(1):61-4. doi: 10.3346/jkms.2005.20.1.61.
Results Reference
background
PubMed Identifier
16802676
Citation
Cohen SM. Jaundice in the full-term newborn. Pediatr Nurs. 2006 May-Jun;32(3):202-8.
Results Reference
background
PubMed Identifier
16585313
Citation
Grohmann K, Roser M, Rolinski B, Kadow I, Muller C, Goerlach-Graw A, Nauck M, Kuster H. Bilirubin measurement for neonates: comparison of 9 frequently used methods. Pediatrics. 2006 Apr;117(4):1174-83. doi: 10.1542/peds.2005-0590.
Results Reference
background
PubMed Identifier
9307164
Citation
Hansen TW. Acute management of extreme neonatal jaundice--the potential benefits of intensified phototherapy and interruption of enterohepatic bilirubin circulation. Acta Paediatr. 1997 Aug;86(8):843-6. doi: 10.1111/j.1651-2227.1997.tb08608.x.
Results Reference
background
PubMed Identifier
10613092
Citation
Lindgren C, Nilsson T. [Treatment of neonatal hyperbilirubinemia with BiliBed]. Tidsskr Nor Laegeforen. 1999 Nov 10;119(27):4027-9. Norwegian.
Results Reference
background
PubMed Identifier
16585312
Citation
Maisels MJ, Kring E. Transcutaneous bilirubin levels in the first 96 hours in a normal newborn population of > or = 35 weeks' gestation. Pediatrics. 2006 Apr;117(4):1169-73. doi: 10.1542/peds.2005-0744.
Results Reference
background
PubMed Identifier
16882840
Citation
Maisels MJ. What's in a name? Physiologic and pathologic jaundice: the conundrum of defining normal bilirubin levels in the newborn. Pediatrics. 2006 Aug;118(2):805-7. doi: 10.1542/peds.2006-0675. No abstract available.
Results Reference
background
PubMed Identifier
18305267
Citation
Maisels MJ, McDonagh AF. Phototherapy for neonatal jaundice. N Engl J Med. 2008 Feb 28;358(9):920-8. doi: 10.1056/NEJMct0708376. No abstract available.
Results Reference
background
PubMed Identifier
16966662
Citation
Maisels MJ, Newman TB. Surveillance of severe neonatal hyperbilirubinemia: a view from south of the border. CMAJ. 2006 Sep 12;175(6):599. doi: 10.1503/cmaj.060960. No abstract available.
Results Reference
background
PubMed Identifier
16672700
Citation
Newman TB, Liljestrand P, Jeremy RJ, Ferriero DM, Wu YW, Hudes ES, Escobar GJ; Jaundice and Infant Feeding Study Team. Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more. N Engl J Med. 2006 May 4;354(18):1889-900. doi: 10.1056/NEJMoa054244.
Results Reference
background
PubMed Identifier
15699303
Citation
Newman TB, Liljestrand P, Escobar GJ. Combining clinical risk factors with serum bilirubin levels to predict hyperbilirubinemia in newborns. Arch Pediatr Adolesc Med. 2005 Feb;159(2):113-9. doi: 10.1001/archpedi.159.2.113.
Results Reference
background
PubMed Identifier
11389241
Citation
Rubaltelli FF, Gourley GR, Loskamp N, Modi N, Roth-Kleiner M, Sender A, Vert P. Transcutaneous bilirubin measurement: a multicenter evaluation of a new device. Pediatrics. 2001 Jun;107(6):1264-71. doi: 10.1542/peds.107.6.1264.
Results Reference
background
PubMed Identifier
10839875
Citation
Seidman DS, Moise J, Ergaz Z, Laor A, Vreman HJ, Stevenson DK, Gale R. A new blue light-emitting phototherapy device: a prospective randomized controlled study. J Pediatr. 2000 Jun;136(6):771-4.
Results Reference
background
PubMed Identifier
12673261
Citation
Seidman DS, Moise J, Ergaz Z, Laor A, Vreman HJ, Stevenson DK, Gale R. A prospective randomized controlled study of phototherapy using blue and blue-green light-emitting devices, and conventional halogen-quartz phototherapy. J Perinatol. 2003 Mar;23(2):123-7. doi: 10.1038/sj.jp.7210862.
Results Reference
background
PubMed Identifier
14684236
Citation
Shapiro SM. Bilirubin toxicity in the developing nervous system. Pediatr Neurol. 2003 Nov;29(5):410-21. doi: 10.1016/j.pediatrneurol.2003.09.011.
Results Reference
background
PubMed Identifier
16603425
Citation
Smitherman H, Stark AR, Bhutani VK. Early recognition of neonatal hyperbilirubinemia and its emergent management. Semin Fetal Neonatal Med. 2006 Jun;11(3):214-24. doi: 10.1016/j.siny.2006.02.002.
Results Reference
background
PubMed Identifier
17208161
Citation
Stokowski LA. Fundamentals of phototherapy for neonatal jaundice. Adv Neonatal Care. 2006 Dec;6(6):303-12. doi: 10.1016/j.adnc.2006.08.004. Erratum In: Adv Neonatal Care. 2007 Apr;7(2):65.
Results Reference
background

Learn more about this trial

Light-emitting Diodes (LED) Phototherapy for Hyperbilirubinemia of Term Newborn

We'll reach out to this number within 24 hrs